Akorn, Inc. operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Akorn with three other
pharmaceutical manufacturers in North America:
sales of $1.06 billion
Biomarin Pharmaceutical Inc
of which 32%
was Vimizim), and
Opko Health Incorporation
of which 83%
During the year ended December of 2016, sales at
Akorn were $1.12 billion.
increase of 13.4%
versus 2015, when the company's sales were $985.08 million.
This was the fifth consecutive year of sales increases at Akorn
(and since 2011, sales have increased a total of 716%).
Sales of Prescription Pharmaceuticals saw an increase
14.0% in 2016, from
$924.47 million to $1.05 billion.